The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
Information source: University of Iowa
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Major Depressive Disorder
Intervention: memantine (Drug); Placebo (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: University of Iowa Official(s) and/or principal investigator(s):
Jerry L Lewis, MD, Principal Investigator, Affiliation: University of Iowa Hospitals and Clinic
Overall contact:
Jerry L. Lewis, MD, Phone: 319-384 5630, Email: jerry-lewis@uiowa.edu
Summary
The purpose of this study is to determine whether memantine will enhance the therapeutic of
effect on depression and prevent memory and other cognitive problems caused by ECT.
Clinical Details
Official title: Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Assessment of whether Memantine protects memory and cognitive impairment caused by ECT.
Secondary outcome: Whether memantine will improve response of Depression to Electroconvulsive therapy.
Detailed description:
Patients will be assigned randomly either to a treatment group or a placebo groups. All
patients in both groups will be receiving standard ECT. The treatment group will receive
memantine. All patients will be given a battery of cognitive tests and test of depression
before ECT treatments start, after the 6th ECT treatment and after the completions of ECT.
An analysis will be performed to see if memantine causes any impact on the response to ECT
and prevents memory and cognitive impairment.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Meets criteria for Major Depressive disorder
Exclusion Criteria:
- Neurological disease
- Mental retardation
- Seizure disorder
Locations and Contacts
Jerry L. Lewis, MD, Phone: 319-384 5630, Email: jerry-lewis@uiowa.edu
University of Iowa hosptitals and clinic, Iowa City, Iowa 50208, United States; Not yet recruiting
Jerry L Lewis, MD, Phone: 319-384-5630, Email: jerry-lewis@uiowa.edu
Laurie M McCormick, MD, Phone: 319-384-7136, Email: laruie-mccormick@uiowa.edu
Jerry L Lewus, MD, Principal Investigator
Additional Information
Starting date: November 2009
Last updated: October 1, 2009
|
